This story was originally published by Targeted Oncology Hearn Jay Cho, MD, PhD, chief medical officer, Multiple Myeloma Research Foundation (MMRF), and associate professor at Mount Sinai Hospital Ruttenberg Treatment Center, discusses the goals of the CureCloud study, an historic initiative of the Multiple Myeloma Research Foundation (MMRF), a leader in the acceleration of efforts...Continue Reading
This was originally published by AJMC The bone marrow (BM) microenvironment is believed to play a key role in the evolution of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM), but a new commentary calls attention to another factor that might be involved in the chain of evolution: the gut microbiome. Writing in...Continue Reading
This was originally posted by Cision PR Newswire SALT LAKE CITY, July 9, 2020 /PRNewswire/ — HealthTree®, the first online portal for multiple myeloma cancer patients to find their best treatment options and help accelerate a cure, today announced the launch of HealthTree University (HTU), the first comprehensive resource that empowers multiple myeloma patients to become experts in...Continue Reading
This article was originally published by Cancer Network Cellectis recently announced the FDA placed its MELANI-01 trial treating multiple myeloma on clinical hold following the submission of a patient’s safety report. The FDA placed the MELANI-01 trial on hold following the submission of a safety report, according to a Cellectis press release. The safety report...Continue Reading
However, when followed by immunomodulatory drugs, researchers found that autologous stem cell transplant can be safely used in this patient population, regardless of CHIP status. Study findings from investigators at the Dana-Farber Cancer Institute indicated that in patients with multiple myeloma treated with autologous stem cell transplant (ASCT), the presence of clonal hematopoiesis of indeterminate...Continue Reading
This article was originally published by Healio Once-weekly selinexor, bortezomib and dexamethasone improved outcomes compared with twice-weekly bortezomib and dexamethasone for pretreated multiple myeloma, according to results presented during the ASCO20 Virtual Scientific Program. Findings from the randomized phase 3 BOSTON study showed prolonged PFS and a higher objective response rate in the experimental group....Continue Reading
This article was originally published by AJMC There are promising signs that chimeric antigen receptor (CAR) T-cell therapies might lead to meaningful advances in the therapy of multiple myeloma. However, investigators will first need to clear a number of key hurdles. Chimeric antigen receptor (CAR) gene-modified T-cell therapy appears to have considerable promise for patients with multiple...Continue Reading
This article originally published by OncLive Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses stem cell mobilization multiple myeloma. Although stem cell mobilization is successful in the majority of patients with multiple myeloma, the use of granulocyte colony-stimulating factor (G-CSF) used alone is associated with up to a 10% failure rate, Kumar explains....Continue Reading
The impact of age, ethnicity and socio-economic deprivation in the era of novel anti-myeloma agents is unclear. Using linked national data from New Zealand, we evaluated the incidence, prevalence and overall survival (OS) of individuals who were diagnosed with myeloma between 2004 and 2016. The crude incidence rate increased from 5.42 to 8.47/100 000 and...Continue Reading
